Acute coronary syndrom
Conditions
Interventions
hydroxychloroquine:hydroxychloroquine 200mg bid
placebo:placebo 200mg bid
Sponsors
Peking University First Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-85 years; 2. Diagnosed with ACS (STEMI, NSTEMI or UA); 3. PCI has been performed; 4. On the 30th day of ACS onset, plasma hsCRP was more than or equal to 2 mg/L.
Exclusion criteria
Exclusion criteria: 1. There are contraindications for the use of hydroxychloroquine, such as porphyria, psoriasis, retinopathy and allergy to 4-chloroquinoline compounds; 2. ACS is caused by operation, trauma, gastrointestinal bleeding or PCI, or its complications; 3. STEMI, NSTEMI or UA occurred in patients who had been hospitalized for other reasons; 4. Combined with other anti-inflammatory drugs, such as methotrexate, NSAIDs, glucocorticoids, cyclophosphamide, etc; 5. Combined with systemic lupus erythematosus, rheumatoid arthritis, Sjogren's syndrome and other chronic inflammatory diseases; 6. Complicated with chronic infection or acute infectious diseases; 7. Major neuropathy and muscle disease caused by any reason (it may be aggravated by the use of hydroxychloroquine); 8. Severe arrhythmia, severe cardiac insufficiency, anemia (Hgb 115umol/L or eGFR = 470ms (male), QTc >= 480ms (female); 14. Elderly patients: older than 85 years old; 15. Any condition (such as travel, language barrier, mental disorders,etc.) that the researcher believes can significantly limit the completion of the patient's follow-up; 16. There are serious coexisting diseases leading to life expectancy <= 6 months; 17. People who have participated in other clinical studies.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| high sensitivity C-reactive protein, hsCRP;interleukin-6, IL-6; | — |
Secondary
| Measure | Time frame |
|---|---|
| Galectin-3; | — |
Countries
China
Contacts
Public ContactQiuping Shi
Peking University First Hospital
Outcome results
None listed